中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2014年
11期
9-12,16
,共5页
尿激酶%动脉溶栓%血管内支架植入%急性脑梗死
尿激酶%動脈溶栓%血管內支架植入%急性腦梗死
뇨격매%동맥용전%혈관내지가식입%급성뇌경사
Urokinase%Arterial thrombolysis%Endovascular stent implantation%Acute cerebral infarction
目的:探讨动脉溶栓联合血管内支架植入在治疗急性脑梗死患者中应用的效果及安全性。方法将62例急性脑梗死患者随机分为支架组和药物组,每组31例。支架组患者在尿激酶动脉溶栓后联合血管内支架植入治疗;药物组在尿激酶动脉溶栓后以常规药物治疗。于术后1、7、14、21d进行NIHSS评分,并综合评定预后及血管再通情况。结果支架组NIHSS评分明显低于药物组,显效率、有效率和血管再通率分别为80.7%、100.0%和100.0%,明显高于药物组的38.7%、61.3%和61.3%(P<0.05)。结论动脉溶栓联合血管内支架植入在治疗急性脑梗死患者中应用,效果确切,并发症少,是一种安全有效的治疗方法。
目的:探討動脈溶栓聯閤血管內支架植入在治療急性腦梗死患者中應用的效果及安全性。方法將62例急性腦梗死患者隨機分為支架組和藥物組,每組31例。支架組患者在尿激酶動脈溶栓後聯閤血管內支架植入治療;藥物組在尿激酶動脈溶栓後以常規藥物治療。于術後1、7、14、21d進行NIHSS評分,併綜閤評定預後及血管再通情況。結果支架組NIHSS評分明顯低于藥物組,顯效率、有效率和血管再通率分彆為80.7%、100.0%和100.0%,明顯高于藥物組的38.7%、61.3%和61.3%(P<0.05)。結論動脈溶栓聯閤血管內支架植入在治療急性腦梗死患者中應用,效果確切,併髮癥少,是一種安全有效的治療方法。
목적:탐토동맥용전연합혈관내지가식입재치료급성뇌경사환자중응용적효과급안전성。방법장62례급성뇌경사환자수궤분위지가조화약물조,매조31례。지가조환자재뇨격매동맥용전후연합혈관내지가식입치료;약물조재뇨격매동맥용전후이상규약물치료。우술후1、7、14、21d진행NIHSS평분,병종합평정예후급혈관재통정황。결과지가조NIHSS평분명현저우약물조,현효솔、유효솔화혈관재통솔분별위80.7%、100.0%화100.0%,명현고우약물조적38.7%、61.3%화61.3%(P<0.05)。결론동맥용전연합혈관내지가식입재치료급성뇌경사환자중응용,효과학절,병발증소,시일충안전유효적치료방법。
Objective To discuss the safety and efficacy of intra-arterial thrombolytic therapy in combination with endovascular sent implantation on the patients of acute cerebral infarction.Methods 62 patients with acute cerebral Infarction were divided into two groups,the stent group and the medicine group,31 cases in each group.The patients in the stent group were treated with endovascular stent therapy after intra-arterial thrombolysis therapy,while the patients in the medicine group were treated with drug.The NIHSS(National Institutes of Health Stroke Scale)scores ,the Comprehensive evaluation of the prognosis and the condition of recanalization of blood vessel were evaluated on the 1st day,7th,14th as well as 21th day after PTA.Results The scores of NIHSS in the stent group were lowered than the medicine group.The significant efficiency was 80.7%,the effective rate was 100.0%and the reunobstructed rate was 100.0%in the stent group,were significantly higher than that of drug group,when they were 38.7%,61.3%and 61.3%(P < 0.05). Conclusion The combined therapy of acute cerebral infarction with intra-arterial thrombolytic and endovascular sent implantation is more effective and safer,it may keep minimize the adverse effects.